more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$83.49 USD

+1.16 (1.41%)

Updated Jun 28, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LGND vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on October 26,2023

LGND vs. ILMN: Which Stock Is the Better Value Option?

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research Published on October 25,2023

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on October 24,2023

Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.

Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term

by Zacks Equity Research Published on October 24,2023

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

LGNDPositive Net Change

Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?

by Zacks Equity Research Published on October 23,2023

Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

by Zacks Equity Research Published on October 23,2023

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research Published on October 23,2023

Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.